At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 30 enrolled
Drug / intervention
Atenolol +2 moredrug
Likely dose
Atenolol 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Open-label, Multicenter, Cross-over Trial to Evaluate the Efficacy of a 20 Week Treatment of Valsartan 320 mg Versus Atenolol 100 mg in Combination With Hydrochlorothiazide on Microcirculation in Hypertensive Patients
In Brief
A Phase 3 clinical trial evaluating Atenolol, Hydrochlorothiazide (HCTZ)), and 1 other intervention for Hypertension. Completed, enrolled 30 participants across 2 sites in 2 countries.
Detailed Summary
This study evaluated the effect of valsartan on small vessel blood flow in patients with mild-to-moderate hypertension in direct comparison to atenolol and hydrochlorothiazide.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesGermany, Switzerland
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2005
First PostedNov 2006
Primary CompletionDec 2007
TodayJul 2026
First PostedNov 7, 2006
Enrollment StartDec 1, 2005
Primary CompletionDec 1, 2007
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 19.7 years ago
Interventions
Atenololdrug
100 mg tablets orally once a day (od) in the morning.
Hydrochlorothiazide (HCTZ))drug
12.5 or 25 mg tablets orally once a day (od) in the morning.
Valsartandrug
80 mg, 160 mg, or 320 mg tablets orally once a day in the morning